Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism

Tsujikawa, LM; Fu, L; Das, S; Halliday, C; Rakai, BD; Stotz, SC; Sarsons, CD; Gilham, D; Daze, E; Wasiak, S; Studer, D; Rinker, KD; Sweeney, M; Johansson, JO; Wong, NCW; Kulikowski, E

Kulikowski, E (reprint author), Resverlogix Corp, 300,4820 Richard Rd SW, Calgary, AB T3E 6L1, Canada.

CLINICAL EPIGENETICS, 2019; 11 ():

Abstract

BackgroundApabetalone (RVX-208) is a bromodomain and extraterminal protein inhibitor (BETi) that in phase II trials reduced the relative risk (RR) of ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索